Literature DB >> 7687617

IL-4, but not tumor necrosis factor-alpha, increases endothelial cell adhesiveness for lymphocytes by activating a cAMP-dependent pathway.

P Galéa1, G Thibault, M Lacord, P Bardos, Y Lebranchu.   

Abstract

IL-4 and TNF-alpha increase endothelial cell adhesiveness for PBL by promoting the expression of adhesion molecules. We investigated the intracellular cAMP involvement in the increased endothelial cell adhesivity induced by IL-4 or TNF-alpha. We showed that both IL-4 and TNF-alpha increased intracellular cAMP in endothelial cells (EC). Furthermore, dibutyryl-cAMP and forskolin (which increased intracellular cAMP) increased basic EC adhesivity for PBL. The co-stimulation of EC with cAMP elevating agents and TNF-alpha, but not IL-4, resulted in an additive increase in EC adhesiveness. 2',5' dideoxyadenosine, an inhibitor of adenylate cyclase, decreased PBL adhesion to IL-4- but not TNF-alpha-treated EC. Similarly, HA1004, a protein kinase A inhibitor, totally reversed the IL-4 but not TNF-alpha effect on EC adhesiveness, whereas H7, a protein kinase C inhibitor, did not antagonise cytokine-enhanced EC adhesivity. These results indicate that IL-4, but not TNF-alpha, uses a cAMP-dependent pathway to increase PBL adhesion. Furthermore, we showed that cAMP elevation in EC did not induce vascular cell adhesion molecule 1, the only identified adhesion molecule induced by IL-4, indicating that a rise in cAMP in EC promotes an as yet unidentified adhesion pathway. Our results show that IL-4 increases EC adhesiveness for PBL through activation of protein kinase A by promoting an unidentified adhesion pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687617

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Interleukin-4, Oxidative Stress, Vascular Inflammation and Atherosclerosis.

Authors:  Yong Woo Lee; Paul H Kim; Won Hee Lee; Anjali A Hirani
Journal:  Biomol Ther (Seoul)       Date:  2010-04       Impact factor: 4.634

2.  Role of NADPH oxidase in interleukin-4-induced monocyte chemoattractant protein-1 expression in vascular endothelium.

Authors:  Yong Woo Lee; Won Hee Lee; Paul H Kim
Journal:  Inflamm Res       Date:  2010-03-28       Impact factor: 4.575

3.  Attenuation of experimental atherosclerosis by interleukin-19.

Authors:  Stephen Ellison; Khatuna Gabunia; Sheri E Kelemen; Ross N England; Rosario Scalia; James M Richards; A Wayne Orr; Wayne Orr; James G Traylor; Thomas Rogers; William Cornwell; Lisa M Berglund; Isabel Goncalves; Maria F Gomez; Michael V Autieri
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-15       Impact factor: 8.311

4.  Effects of protein tyrosine kinase inhibitors on cytokine-induced adhesion molecule expression by human umbilical vein endothelial cells.

Authors:  M J May; C P Wheeler-Jones; J D Pearson
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  Association of single-nucleotide polymorphisms in JAK3, STAT4, and STAT6 with new cardiovascular events in incident dialysis patients.

Authors:  C John Sperati; Rulan S Parekh; Yvette Berthier-Schaad; Bernard G Jaar; Laura Plantinga; Nancy Fink; Neil R Powe; Michael W Smith; Josef Coresh; W H Linda Kao
Journal:  Am J Kidney Dis       Date:  2009-03-12       Impact factor: 8.860

6.  Oxidative mechanisms of IL-4-induced IL-6 expression in vascular endothelium.

Authors:  Yong Woo Lee; Won Hee Lee; Paul H Kim
Journal:  Cytokine       Date:  2009-10-12       Impact factor: 3.861

7.  Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease.

Authors:  M K Racke; A Bonomo; D E Scott; B Cannella; A Levine; C S Raine; E M Shevach; M Röcken
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

8.  Interleukin-4 (IL-4) enhances and soluble interleukin-4 receptor (sIL-4R) inhibits histamine release from peripheral blood basophils and mast cells in vitro and in vivo.

Authors:  B Niggemann; T Zuberbier; U Herz; K Enssle; U Wahn; H Renz
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.